UNSPSC 51362509: Etodroxizine dimaleate

This classification denotes a sedative and hypnotic C23H31ClN2O3.2C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier O9NQM95R01, chemically known as ethanol, 2-(2-(2-(4-((4-chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)ethoxy)-, (2z)-2-butenedioate (1:2) (salt), but more generally known as etodroxizine dimaleate, which bears US NIH Compound Identifier 6446285. Most nations, for tariff and trade purposes, schedule etodroxizine dimaleate under HS 29335995 and SITC 51576.

As of Q4 2014, ETODROXIZINE DIMALEATE remains US FDA's Preferred Term for this commodity. SMILES: C1CCC(CC1)C(N2CCN(CC2)CCOCCOCCO)C3CCC(CC3)CL.C(=C\C(=O)O)\C(=O)O.C(=C\C(=O)O)\C(=O)O.

UNSPSC 51362509 Etodroxizine dimaleate is a Commodity code that in practice encompasses a broad spectrum of pharmaceutical products and drug-related procurement beyond its nominal single-ingredient designation. State and local solicitations under this code reflect purchasing for naloxone, generic multi-source pharmaceuticals, over-the-counter products, and direct-to-manufacturer prescription programs that serve public health agencies, health and human services departments, and cooperative purchasing alliances. Issuing bodies include county health departments, state health and human services commissions, and multistate cooperative purchasing organizations. Vendors are typically required to hold current Good Manufacturing Practices certification, comply with Drug Supply Chain Security Act requirements, maintain substantial commercial general liability and professional liability insurance, and demonstrate capacity to supply through authorized pharmaceutical wholesalers with electronic data interchange capability and chargeback systems.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, due July 26, 2023 (note: date mismatch in source). The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program. The Minnesota Department of Administration's Office of State Procurement, administering the Minnesota Multistate Cooperative Purchasing Alliance, issued RFP S1070000015802 on January 20, 2026 for generic multi-source pharmaceuticals and OTC products serving state and local government facilities across Minnesota and Oregon, with proposals due March 26, 2026. The MMCAP procurement emphasizes price competitiveness (weighted at 75 percent) and requires vendors to maintain relationships with at least two of three authorized wholesalers and comply with FDA requirements and manufacturing-date shelf-life standards.